Clinical development of olaparib, a PARP inhibitor, leading to improved outcomes for cancer patients
- Submitting institution
-
Institute of Cancer Research: Royal Cancer Hospital (The)
- Unit of assessment
- 1 - Clinical Medicine
- Summary impact type
- Health
- Request cross-referral to
- -
- Is this case study continued from a case study submitted in 2014?
- No
- Underpinning research subjects
-
- Clinical Sciences
- Oncology And Carcinogenesis
- Public Health And Health Services
3. References to the research
5. Sources to corroborate the impact
Additional contextual information
Grant funding
Grant number |
Value of grant |
C51/A6883 |
£3,835,960 |
A7401 |
£3,767,251 |
None given (ECMC 2007) |
£1,250,000 |
C12540/A15573 |
£750,000 |
None given (ECMC 2012) |
£750,000 |
C12540/A25128 |
£1,282,041 |
None given (ECMC 2017) |
£1,282,041 |
None given (BRC 2007) |
£46,800,000 |
BRC-2011-10059 |
£61,543,735 |
IS-BRC-1215-20021 |
£43,074,315 |
BBC024X (internal) |
£30,872,915 |
C1178/A7851 |
£2,302,100 |
C12540/A12829 |
£231,601 |
C12540/A13230 |
£282,970 |
C1491/A9895 |
£5,010,603 |
C1491/A15955 |
£5,901,462 |
SU2C-AACR-DT0712 |
£6,312,000 |
PG14-010-TR2 |
£315,895 |
TLD-S15-006 |
£103,923 |
MRCCRTF13001 |
£250,686 |
CEO13_2002 |
£6,454,883 |
PIIF-GA-2013-625792 |
£197,754 |
PCF16YOUN11 |
£142,020 |
C12540/A20447 |
£236,883 |
C1491/A25351 |
£6,456,485 |
C347/A15403 |
£11,023,183 |
C309/A25144 |
£21,523,238 |
- Countries
-
- USA
- Austria
- Belgium
- Bulgaria
- Croatia
- Cyprus
- Czechia
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Malta
- Netherlands
- Poland
- Portugal
- Romania
- Slovakia
- Slovenia
- Spain
- Sweden
- Iceland
- Liechtenstein
- Norway
- UK
- Canada
- Japan
- Brazil
- Australia
- China
- Israel
- South Korea
- Russia
- Argentina
- Taiwan
- Turkey
- Formal partners
-
- The Royal Marsden NHS Foundation Trust
- Stand Up to Cancer - Prostate Cancer Foundation Prostate Dream Team
- KuDOS
- AstraZeneca
- Merck Sharp and Dohme
- Funding programmes
-
- Cancer Research UK: Funding to the Section of Medicine (2006 to 2011)
- Cancer Research UK: Experimental Cancer Medicine Centre (2007)
- Department of Health: Experimental Cancer Medicine Centre (2007)
- Cancer Research UK: Experimental Cancer Medicine Centre (2012)
- Department of Health: Experimental Cancer Medicine Centre (2012)
- Cancer Research UK: Experimental Cancer Medicine Centre (2017)
- Department of Health: Experimental Cancer Medicine Centre (2017)
- The National Institute for Health Research Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research (2007)
- The National Institute for Health Research Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research (2011)
- The National Institute for Health Research Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research (2017)
- Breakthrough Breast Cancer (now Breast Cancer Now) Centre Core Grant 2003 to 2010
- Cancer Research UK: Chair of Medical Oncology
- Cancer Research UK: CRUK/11/029: TO-PARP: Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer
- Cancer Research UK: Identification and Molecular Characterisation of metastatic sporadic castration resistant prostate cancers (mCRPC)
- Cancer Research UK: ICR Clinical Trials and Statistic Unit Programme Grant (2008 to 2013)
- Cancer Research UK: ICR Clinical Trials and Statistic Unit Programme Grant (2013 to 2018)
- Stand Up To Cancer : Prostate Dream Team Translational Cancer Research Grant - Precision Therapy of Advanced Prostate Cancer
- Prostate Cancer UK: Developing an analytically validated biomarker assay to identify patients with BRCAness who will benefit from treatment with PARP inhibitors or platinum therapy
- Prostate Cancer UK: Integrative prostate cancer genomics to improve castration-resistant prostate cancer treatment by molecular stratification
- Medical Research Council: Predictive biomarkers of response to DNA repair targeting agents in sporadic prostate cancer
- Prostate Cancer UK: London Movember Centre of Excellence
- European Commission: Marie Skłodowska-Curie Individual Fellowship - CDELP
- Prostate Cancer Foundation: Defining the landscape and clinical relevance of ATM defects in lethal prostate cancer
- Cancer Research UK: TOPARP - Phase II
- Cancer Research UK: ICR Clinical Trials and Statistic Unit Programme Grant (2018-2023)
- Cancer Research UK: CRUK Centre at ICR and Royal Marsden (2012)
- Cancer Research UK: CRUK Centre at ICR and Royal Marsden (2016)
- Global research identifiers
-
- grid.11485.39
- grid.57981.32
- grid.451056.3
- grid.458394.7
- grid.430427.6
- grid.453276.1
- grid.420006.0
- grid.270680.b
- grid.453146.1
- Name of funders
-
- Cancer Research UK
- Department of Health
- National Institute for Health Research
- Breakthrough Breast Cancer (now Breast Cancer Now)
- Stand Up To Cancer (part of the Entertainment Industry Foundation)
- Prostate Cancer UK
- Medical Research Council
- European Commission
- Prostate Cancer Foundation
- Researcher ORCIDs
-
- 0000-0002-2034-595X
- 0000-0001-5999-5020
- 0000-0003-1446-7878
- 0000-0002-3698-6241
- 0000-0002-4811-7983
- 0000-0002-3226-0515
- 0000-0001-8715-2901
- 0000-0001-8666-1608